The anticipated availability and subsequent approval in Canada of the first gene-targeted therapy for certain people with amyotrophic lateral sclerosis (ALS) has transformed how doctors in the North American nation approach genetic testing for the rare neurodegenerative disease, according to a new study. Over the last five years, Canadian…
News
A feature documentary airing on PBS delves into a man’s final years living with amyotrophic lateral sclerosis (ALS), offering an intimate portrait of resilience, caregiving, and enduring love while exploring how culture and identity shaped his experience with the disease. The film “…
A post-marketing analysis of safety reports found that many of the strongest signals involving Qalsody (tofersen) in people with amyotrophic lateral sclerosis (ALS) were related to the spinal procedures used to administer it. Other reporting signals involved neurological and inflammatory events. The study, based on 409 reports submitted…
A self-balancing, hands-free robotic exoskeleton designed for people with severe gait impairment was safe and well tolerated in a small pilot study of amyotrophic lateral sclerosis (ALS) patients who could still walk. While six weeks of walking practice with the Atalante exoskeleton did…
Targeting a specific part of the TDP-43 protein can prevent toxic protein clumping that drives amyotrophic lateral sclerosis (ALS) without disrupting the protein’s normal function, a new study shows. “Current [U.S.-approved] treatments for ALS provide only modest benefits. There is an urgent need for a real breakthrough,” Xinglong Wang,…
An expanded access program (EAP) at Massachusetts General Hospital (MGH) shows that such programs can work, a study found. The program enabled 11 people with SOD1-associated amyotrophic lateral sclerosis (ALS) who could not participate in clinical trials to receive Qalsody (tofersen) before its U.S. approval. In addition, it…
More than one in 10 people with amyotrophic lateral sclerosis (ALS) harbor at least one known disease-causing mutation, according to a new profile from the Strategic ALS Australia Systems Genomics Consortium (SALSA-SGC). The multi-site research consortium brings together major ALS clinics across Australia to collect clinical data and biological…
A new wearable soft-glove device has successfully restored hand function in a man with amyotrophic lateral sclerosis (ALS), allowing him to grip objects and feed himself independently. The device was developed by a team of scientists in Germany who worked in direct collaboration with the patient himself. The man…
Neuralink, a company developing brain-computer interface (BCI) devices aimed at restoring independence to people with paralysis caused by conditions such as amyotrophic lateral sclerosis (ALS), has tested a new implant approach in which electrode threads were inserted through the dura without cutting it open. The dura is the…
A University of Melbourne spinout company is developing a less invasive brain-computer interface that could one day allow people with impaired speech, including those with amyotrophic lateral sclerosis (ALS), to communicate by attempting to say words. Unlike many current brain-computer interface prototypes, which can involve invasive surgery…
Recent Posts
- How new gene therapies are transforming genetic testing for ALS
- A trip to the ER makes me thankful I still have my parenting partner
- PBS documentary on runner with ALS explores identity, caregiving
- A new wheelchair means making adjustments mentally and physically
- Real-world study sheds new light on safety of approved ALS drug